secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2022-06-10T23:59:59+00:00
Accession:  0001193125-22-171957
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulcrum reports positive Phase 1b data for FTX-6058 in sickle cell disease; HbF up 6.3%
--------------------------------------------------------------------------------

- FTX-6058 achieved up to 6.3% increase in fetal hemoglobin (HbF) over baseline in Phase 1b trial.
- Three evaluable subjects all showed HbF increases by day 28; maximal levels may not yet be reached.
- FTX-6058 was generally well-tolerated; no serious TEAEs or discontinuations due to TEAEs.
- Company plans to complete enrollment in current and two additional dose cohorts by end of 2022, with registrational trial start in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000119312522171957/0001193125-22-171957-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000119312522171957/d369471d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-171957

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer